Lung Cancer Clinical Trials UCI 13-55 A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) (Ou) UC 06-15 Optical Coherence Tomography of Airway and Pleural Disorders (Brenner) UCI 06-16 Optical Coherance Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer (Brenner) DIAGNOSTIC **UCI 14-18 A Phase III, Open Label, Randomised Study to Assess the Safety and Efficacy of AZD9291 versus PlatinumBased Doublet Chemotherapy in Second-Line Patients with Locally Advanced or Metastatic NSCLC whose Disease has Progressed with Previous EGFR TKI Therapy and whose Tumours are EGFR Mutation and T790M Mutation Positive (AURA3) FAILED EGFR TKI LUNG CANCER 1st Line Therapeutic MESOTHELIOMA SWOG-S0819 (S) UCI 11-41 **UCI 14-32 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel /Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced NonSmall Cell Lung Cancer (NSCLC) A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects Randomized, Multicenter, Phase III, Open-Label Study Of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma KinasePositive Advanced Non-Small Cell Lung Cancer with BRAF V600E mutation positive metastatic (stage IV) NSCLC For more details contact 1-877-UC-STUDY OR [email protected] FAILED PLATINUM-BASED CHEMO TX **OPENING SOON SWOG-S0905 A Phase I/Randomized Phase II study of Cediranib (NSC #732208) versus Placebo in Combination with Cisplatin and Pemetrexed in chemonaive patients with Malignant Pleural Mesothelioma (Ou) UCI 13-57 SUNRISE: A Phase III, Randomized, DoubleBlind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone as Second-Line Therapy in Patients with Stage IIIb/IV Non-Squamous Non-SmallCell Lung Cancer (Ou) UCI 14-04 Phase 3, Randomized, Placebo-Controlled, Doubleblind, Multi-Center, TwoPart Study of Patritumab (U3-1287) in Combination with Erlotinib in EGFR Wildtype Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy (Ou) V. Feb 2015 Lung Cancer Clinical Trials MULTIPLE DISEASE SITES **UCI 13-49 Open-Label DoseEscalation Trial to Evaluate the Safety, PK, and PD of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies (Ou) ADVANCED SOLID TUMORS **UCI 14-39 Phase I, Two-part, Multi-Center, NonRandomized, Open Label, Multiple Dose First in Human Study of DS-6051B, an Oral ROS1 and NTRK Inhibitor, in Subjects with Advanced Solid Tumors (Ou) UCI 14-01 Phase 1/2a, Multicenter, Open-Label Study of Oral Rxdx-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TRKA, TRKB, TRKC, ROS1, NTRK1-3 or ALK Molecular Alterations (Ou) UCI 13-35 (S) A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Squamous Cell Lung, NSCLC and Advanced Solid Tumors (Ou) **UCI 14-61 A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib UCI 07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a CMET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer For more details contact 1-877-UC-STUDY OR [email protected] LUNG CANCER **UCI 14-68 An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With Anaplastic lymphoma kinaseRearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib **OPENING SOON **UCI 12-44 A Phase II, openlabel study of ponatinib, a multitargeted oral tyrosine kinase inhibitor, in advanced NSCLC harboring RET translocations (Ou) **UCI 14-23 Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced NonSmall Cell Lung Cancer Harboring Specific Molecular Alterations (Ou) **UCI 14-69 A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable NonSmall Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy V. Feb 2015